Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes
about
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age GroupsRole of hematopoietic stem cell transplantation in patients with myeloproliferative disease.Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosisGlutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning.Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation.Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects.Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients.How I treat hepatitis C virus infection in patients with hematologic malignancies.Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics.Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway.Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation.The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation.
P2860
Q26786893-EAF0A4F7-B4D3-49A7-82BA-7D8F4420FC7BQ34625390-541C641F-8945-4847-8546-2EBD99E8114CQ35735663-481B0925-745F-4030-96D9-9A4FAC1AAA56Q35861851-5152C325-9C3F-49A0-BD50-B9BB1E5C27F8Q36125427-E4B22830-0086-473B-A9C1-8AFF8C2EB9EBQ37718826-A92EBB91-080A-48B8-BCEB-0574D6CB21A7Q38174781-DEE59428-EC0D-49F1-AC5B-9DCA8303B85EQ38373316-D141A459-B226-403F-99D5-56F1BC6B401DQ38568355-2F401FE7-08FA-4037-AA31-DF357E4BA811Q38847841-FE9DB11B-DD2F-4488-80B5-E6C663A18D12Q39747715-B9EB3869-F8E8-478A-8FF4-337FD8DB227DQ40604797-F75479ED-8D97-482B-A142-497B017D5A5DQ41653330-9035D8D5-BB8E-43D3-8B4D-319373CF0680Q47116870-23F76176-C7F7-476F-BA26-B1B82BE07E2FQ52552920-DEF289EC-88F5-4DBF-BF18-98329D324B8AQ54686050-9229D4BD-7962-40E2-8296-9739E86D6252Q54978683-85FD5A75-25E5-42A8-B6A4-1229BB72F571
P2860
Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cyclophosphamide followed by i ...... kinetics and clinical outcomes
@en
Cyclophosphamide followed by i ...... inetics and clinical outcomes.
@nl
type
label
Cyclophosphamide followed by i ...... kinetics and clinical outcomes
@en
Cyclophosphamide followed by i ...... inetics and clinical outcomes.
@nl
prefLabel
Cyclophosphamide followed by i ...... kinetics and clinical outcomes
@en
Cyclophosphamide followed by i ...... inetics and clinical outcomes.
@nl
P2093
P2860
P50
P1476
Cyclophosphamide followed by i ...... kinetics and clinical outcomes
@en
P2093
Ami Batchelder
Andrew R Rezvani
George B McDonald
P2860
P304
P356
10.1016/J.BBMT.2013.04.005
P577
2013-04-10T00:00:00Z